| Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines A Bekker, HS Schaaf, HR Draper, L van Der Laan, S Murray, L Wiesner, ... Antimicrobial agents and chemotherapy 60 (4), 2171-2179, 2016 | 91 | 2016 |
| High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial AR Giuliano, MH Botha, M Zeier, ME Abrahamsen, RH Glashoff, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 68 (2), 227-235, 2015 | 43 | 2015 |
| Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial LJ Menezes, U Pokharel, SL Sudenga, MH Botha, M Zeier, ... Sexually transmitted infections 94 (1), 55-61, 2018 | 40 | 2018 |
| Adverse effects of oral second-line antituberculosis drugs in children HS Schaaf, S Thee, L van der Laan, AC Hesseling, AJ Garcia-Prats Expert opinion on drug safety 15 (10), 1369-1381, 2016 | 38 | 2016 |
| Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial AJ Garcia-Prats, EM Svensson, J Winckler, HR Draper, L Fairlie, ... Journal of Antimicrobial Chemotherapy 76 (12), 3237-3246, 2021 | 33 | 2021 |
| Pharmacokinetics and drug-drug interactions of lopinavir-ritonavir administered with first-and second-line antituberculosis drugs in HIV-infected children treated for multidrug … LE van der Laan, AJ Garcia-Prats, HS Schaaf, T Tikiso, L Wiesner, ... Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 00420-17, 2018 | 30 | 2018 |
| Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes H McIlleron, H Hundt, W Smythe, A Bekker, J Winckler, L Van der Laan, ... The International Journal of Tuberculosis and Lung Disease 20 (7), 915-919, 2016 | 26 | 2016 |
| Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study P Denti, RE Wasmann, A Van Rie, J Winckler, A Bekker, H Rabie, ... Clinical Infectious Diseases 75 (1), 141-151, 2022 | 22 | 2022 |
| Probable levofloxacin-associated secondary intracranial hypertension in a child with multidrug-resistant tuberculosis LE van der Laan, HS Schaaf, R Solomons, M Willemse, N Mohamed, ... The Pediatric Infectious Disease Journal 35 (6), 706-708, 2016 | 21 | 2016 |
| Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children KK Radtke, AC Hesseling, JL Winckler, HR Draper, BP Solans, S Thee, ... Clinical Infectious Diseases 74 (8), 1372-1381, 2022 | 16 | 2022 |
| Delamanid added to an optimized background regimen in children with multidrug-resistant tuberculosis: results of a phase I/II clinical trial AJ Garcia-Prats, M Frias, L van der Laan, A De Leon, MT Gler, HS Schaaf, ... Antimicrobial Agents and Chemotherapy 66 (5), e02144-21, 2022 | 10 | 2022 |
| Treatment outcomes and safety in children with rifampicin-resistant TB E Lopez-Varela, AJ Garcia-Prats, JA Seddon, HR Draper, J Winckler, ... The International Journal of Tuberculosis and Lung Disease 26 (2), 133-141, 2022 | 10 | 2022 |
| HPV serostatus pre-and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial SL Sudenga, BN Torres, MH Botha, M Zeier, ME Abrahamsen, ... Papillomavirus Research 3, 50-56, 2017 | 10 | 2017 |
| Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial SL Sudenga, BN Torres, MH Botha, M Zeier, ME Abrahamsen, ... Journal of Infection 72 (1), 60-69, 2016 | 10 | 2016 |
| Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB JL Winckler, HR Draper, HS Schaaf, LE van der Laan, AC Hesseling, ... The international journal of tuberculosis and lung disease: the official …, 2020 | 9 | 2020 |
| Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB JL Winckler, HS Schaaf, HR Draper, H McIlleron, J Norman, ... The International Journal of Tuberculosis and Lung Disease 25 (11), 896-902, 2021 | 8 | 2021 |
| Pharmacokinetics and safety of bedaquiline in human immunodeficiency virus (HIV)-positive and negative older children and adolescents with rifampicin-resistant tuberculosis JA Hughes, BP Solans, HR Draper, HS Schaaf, JL Winckler, ... Clinical Infectious Diseases 75 (10), 1772-1780, 2022 | 4 | 2022 |
| Pharmacokinetics and safety of bedaquiline in HIV-positive and negative older children and adolescents with rifampicin-resistant tuberculosis JA Hughes, BP Solans, HR Draper, HS Schaaf, JL Winckler, ... Clin Infect Dis 75 (10), 1772-1780, 2022 | 4 | 2022 |
| Pharmacokinetics and drug-drug interactions of abacavir and lamuvudine Co-administered with antituberculosis drugs in HIV-positive children treated for multidrug-resistant … LE Van der Laan, AJ Garcia-Prats, HS Schaaf, JL Winckler, H Draper, ... Frontiers in Pharmacology 12, 722204, 2021 | 4 | 2021 |
| QT interval prolongation with one or more QT-prolonging agents used as part of a multidrug regimen for rifampicin-resistant tuberculosis treatment: findings from two pediatric … AM Ali, KK Radtke, AC Hesseling, J Winckler, HS Schaaf, HR Draper, ... Antimicrobial Agents and Chemotherapy 67 (7), e01448-22, 2023 | 3 | 2023 |
